TDMS Study 05114-02 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest HEXACHLOROCYCLOPENTADIENE (HCCPD) DATE: 09/15/94
EXPERIMENT: 05114 TEST: 02 TIME: 07:14:57
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: N01ES2800301 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 55607B
PATHOLOGIST: E. GIDDENS HAILEY, JAMESR. CAS: 77-47-4
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest HEXACHLOROCYCLOPENTADIENE (HCCPD) DATE: 09/15/94
EXPERIMENT: 05114 TEST: 02 TIME: 07:14:57
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01ES2800301 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 55607B
PATHOLOGIST: E. GIDDENS HAILEY, JAMESR. CAS: 77-47-4
MICE(B6C3F1)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Cortex
Adrenal Medulla
Bone Marrow
Brain
Clitoral Gland
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Larynx
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest HEXACHLOROCYCLOPENTADIENE (HCCPD) DATE: 09/15/94
EXPERIMENT: 05114 TEST: 02 TIME: 07:14:57
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01ES2800301 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 55607B
PATHOLOGIST: E. GIDDENS HAILEY, JAMESR. CAS: 77-47-4
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF HEXACHLOROCYCLOPENTADIENE (HCCPD)
====================================================================================================
MALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Harderian Gland Adenoma
Liver Hepatocellular Adenoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Carcinoma
Thyroid Gland: Follicular Cell
Adenoma
All Organs Malignant Lymphoma And Histiocytic Sarcoma
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed,
NOS, or Undifferentiated Cell Type
Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Stomach, Forestomach Squamous Cell Papilloma
All Organs Histiocytic Sarcoma
Malignant Lymphoma And Histiocytic Sarcoma
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed,
NOS, or Undifferentiated Cell Type
Benign Tumors
Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 7/90 (8%) 3/60 (5%) 7/60 (12% 9/190 (5% 5/160 (3% 4/60 (7%) 6/60 (10%) 4/60 (7%) 2/60 (3%) |
|ADJUSTED (b) 19.0% 9.1% 16.7% 8.4% 6.8% | 12.9% 18.8% 12.1% 6.4% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) |
|TERMINAL (d) 6/35 (17% 3/33 (9%) 7/42 (17% 6/102 (6% 5/74 (7%) 4/31 (13%) 6/32 (19%) 2/30 (7%) 1/21 (5%) |
|FIRST INCIDENCE (DAYS) | 627 729 (T) 729 (T) 654 729 (T)| 736 (T) 736 (T) 660 458 (I) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.051N P=0.183N P=0.478N P=0.076N P=0.046N* P=0.324N P=0.387 P=0.631 P=0.493N |
|INCIDENTAL TUMOR |P=0.064N P=0.190N P=0.492N P=0.085N P=0.061N P=0.298N P=0.387 P=0.623N P=0.493N |
|LOGISTIC REGRESSION |P=0.061N P=0.169N P=0.522N P=0.077N P=0.056N P=0.246N P=0.387 P=0.635N P=0.399N |
|COCHRAN-ARMITAGE |P=0.036N* | P=0.162N |
|FISHER EXACT | P=0.377N P=0.300 P=0.224N P=0.092N P=0.372 P=0.641N P=0.340N |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 7/90 (8%) 3/60 (5%) 7/60 (12% 9/190 (5% 6/160 (4% 5/60 (8%) 6/60 (10%) 4/60 (7%) 2/60 (3%) |
|ADJUSTED (b) 19.0% 9.1% 16.7% 8.4% 8.1% | 15.5% 18.8% 12.1% 6.4% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 1/10 (10%) |
|TERMINAL (d) 6/35 (17% 3/33 (9%) 7/42 (17% 6/102 (6% 6/74 (8%) 4/31 (13%) 6/32 (19%) 2/30 (7%) 1/21 (5%) |
|FIRST INCIDENCE (DAYS) | 627 729 (T) 729 (T) 654 729 (T)| 693 736 (T) 660 458 (I) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.093N P=0.183N P=0.478N P=0.076N P=0.076N P=0.262N P=0.520 P=0.510N P=0.358N |
|INCIDENTAL TUMOR |P=0.112N P=0.190N P=0.492N P=0.085N P=0.097N P=0.230N P=0.529 P=0.461N P=0.332N |
|LOGISTIC REGRESSION |P=0.109N P=0.169N P=0.522N P=0.077N P=0.093N P=0.192N P=0.521 P=0.487N P=0.272N |
|COCHRAN-ARMITAGE |P=0.066N | P=0.123N |
|FISHER EXACT | P=0.377N P=0.300 P=0.224N P=0.141N P=0.500 P=0.500N P=0.219N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|Liver |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 0/90 (0%) 1/42 (2%) 0/47 (0%) 2/91 (2%) 0/60 (0%) 0/59 (0%) 1/60 (2%) 0/60 (0%) 0/60 (0%) |
|ADJUSTED (b) 0.0% 2.6% 0.0% 3.6% 0.0% | 0.0% 2.0% 0.0% 0.0% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 0/15 (0%) 0/29 (0%) 1/34 (3%) 0/0 | 0/31 (0%) 0/32 (0%) 0/30 (0%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | --- 687 --- 481 --- | --- 503 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.611N P=0.505 (e) P=0.349 (e) | P=0.617N P=0.513 (e) (e) |
|INCIDENTAL TUMOR |P=0.470 P=0.527 (e) P=0.413 (e) | P=0.279N P=0.282 (e) (e) |
|LOGISTIC REGRESSION |P=0.619 P=0.384 (e) P=0.249 (e) | P=0.543N P=0.471 (e) (e) |
|COCHRAN-ARMITAGE |P=0.621N | P=0.597N |
|FISHER EXACT | P=0.318 (e) P=0.251 (e) | P=0.504 (e) (e) |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 23/90 (26% 16/42 (38% 23/47 (49% 11/91 (12% 1/60 (2%) 6/59 (10%) 10/60 (17%) 7/60 (12%) 6/60 (10%) |
|ADJUSTED (b) 52.8% 87.5% 65.6% 25.2% 0.0% | 16.5% 31.3% 22.5% 21.3% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 1/10 (10% 0/0 0/0 0/10 (0%) 1/20 (5%) |
|INTERIM SACRIFICE 4 (c 3/10 (30% 2/10 (20% 2/10 (20% 1/20 (5%) 0/20 (0%) 1/10 (10%) 0/10 (0%) 0/10 (0%) 1/10 (10%) |
|TERMINAL (d) 16/35 (46% 13/15 (87% 18/29 (62% 8/34 (24% 0/0 | 4/31 (13%) 10/32 (31%) 6/30 (20%) 2/21 (10%) |
|FIRST INCIDENCE (DAYS) | 295 (I) 459 (I) 459 (I) 459 (I) 295 (I)| 458 (I) 736 (T) 718 458 (I) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P<0.001N** P=0.139 P=0.283 P=0.002N** P=0.002N** P=0.496 P=0.222 P=0.483 P=0.417 |
|INCIDENTAL TUMOR |P<0.001N** P=0.134 P=0.192 P=0.006N** P=0.037N* P=0.562 P=0.227 P=0.510 P=0.527 |
|LOGISTIC REGRESSION |P<0.001N** P=0.287 P=0.123 P=0.009N** P=0.090N P=0.522N P=0.221 P=0.517 P=0.558 |
|COCHRAN-ARMITAGE |P<0.001N** | P=0.339N |
|FISHER EXACT | P=0.104 P=0.006 ** P=0.016N* P<0.001N** P=0.221 P=0.513 P=0.607N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 9/90 (10% 7/42 (17% 10/47 (21% 12/91 (13% 0/60 (0%) 4/59 (7%) 2/60 (3%) 4/60 (7%) 1/60 (2%) |
|ADJUSTED (b) 20.5% 22.7% 30.7% 15.5% 0.0% | 11.2% 5.4% 10.8% 4.8% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 2/10 (20% 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 3/35 (9%) 2/15 (13% 8/29 (28% 3/34 (9%) 0/0 | 2/31 (6%) 0/32 (0%) 1/30 (3%) 1/21 (5%) |
|FIRST INCIDENCE (DAYS) | 459 (I) 443 618 393 --- | 634 668 625 736 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.003N** P=0.591 P=0.430 P=0.243N P=0.001N** P=0.326N P=0.328N P=0.633N P=0.300N |
|INCIDENTAL TUMOR |P=0.578 P=0.546N P=0.231 P=0.319 P=0.102N P=0.206N P=0.290N P=0.562N P=0.222N |
|LOGISTIC REGRESSION |P=0.448N P=0.576 P=0.235 P=0.374 P=0.192N P=0.251N P=0.326N P=0.632N P=0.229N |
|COCHRAN-ARMITAGE |P=0.005N** | P=0.195N |
|FISHER EXACT | P=0.207 P=0.063 P=0.331 P=0.009N** P=0.332N P=0.632N P=0.177N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 30/90 (33% 23/42 (55% 30/47 (64% 21/91 (23% 1/60 (2%) 10/59 (17%) 12/60 (20%) 10/60 (17%) 7/60 (12%) |
|ADJUSTED (b) 61.2% 100.0% 82.0% 35.5% 0.0% | 26.7% 35.0% 29.3% 25.5% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 1/10 (10% 0/0 0/0 0/10 (0%) 1/20 (5%) |
|INTERIM SACRIFICE 4 (c 5/10 (50% 2/10 (20% 2/10 (20% 1/20 (5%) 0/20 (0%) 1/10 (10%) 0/10 (0%) 0/10 (0%) 1/10 (10%) |
|TERMINAL (d) 17/35 (49% 15/15 (100 23/29 (79% 10/34 (29% 0/0 | 6/31 (19%) 10/32 (31%) 7/30 (23%) 3/21 (14%) |
|FIRST INCIDENCE (DAYS) | 295 (I) 443 459 (I) 393 295 (I)| 458 (I) 668 625 458 (I) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P<0.001N** P=0.128 P=0.286 P=0.001N** P<0.001N** P=0.476N P=0.436 P=0.583 P=0.557N |
|INCIDENTAL TUMOR |P<0.001N** P=0.128 P=0.093 P=0.032N* P=0.004N** P=0.343N P=0.461 P=0.546N P=0.407N |
|LOGISTIC REGRESSION |P<0.001N** P=0.098 P=0.054 P=0.025N* P=0.020N* P=0.298N P=0.432 P=0.578N P=0.385N |
|COCHRAN-ARMITAGE |P<0.001N** | P=0.163N |
|FISHER EXACT | P=0.016 * P<0.001 ** P=0.085N P<0.001N** P=0.424 P=0.580N P=0.288N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 30/90 (33% 23/42 (55% 30/47 (64% 21/91 (23% 1/60 (2%) 10/59 (17%) 12/60 (20%) 10/60 (17%) 7/60 (12%) |
|ADJUSTED (b) 61.2% 100.0% 82.0% 35.5% 0.0% | 26.7% 35.0% 29.3% 25.5% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 1/10 (10% 0/0 0/0 0/10 (0%) 1/20 (5%) |
|INTERIM SACRIFICE 4 (c 5/10 (50% 2/10 (20% 2/10 (20% 1/20 (5%) 0/20 (0%) 1/10 (10%) 0/10 (0%) 0/10 (0%) 1/10 (10%) |
|TERMINAL (d) 17/35 (49% 15/15 (100 23/29 (79% 10/34 (29% 0/0 | 6/31 (19%) 10/32 (31%) 7/30 (23%) 3/21 (14%) |
|FIRST INCIDENCE (DAYS) | 295 (I) 443 459 (I) 393 295 (I)| 458 (I) 668 625 458 (I) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P<0.001N** P=0.128 P=0.286 P=0.001N** P<0.001N** P=0.476N P=0.436 P=0.583 P=0.557N |
|INCIDENTAL TUMOR |P<0.001N** P=0.128 P=0.093 P=0.032N* P=0.004N** P=0.343N P=0.461 P=0.546N P=0.407N |
|LOGISTIC REGRESSION |P<0.001N** P=0.098 P=0.054 P=0.025N* P=0.020N* P=0.298N P=0.432 P=0.578N P=0.385N |
|COCHRAN-ARMITAGE |P<0.001N** | P=0.163N |
|FISHER EXACT | P=0.016 * P<0.001 ** P=0.085N P<0.001N** P=0.424 P=0.580N P=0.288N |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 13/89 (15% 10/60 (17% 11/60 (18% 41/189 (22 22/160 (14 4/58 (7%) 3/60 (5%) 4/60 (7%) 5/59 (8%) |
|ADJUSTED (b) 33.4% 29.2% 24.4% 35.2% 27.9% | 12.9% 9.4% 11.6% 16.1% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 1/10 (10% 0/0 0/0 1/10 (10% 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 1/10 (10% 0/10 (0%) 1/10 (10% 1/20 (5%) 2/20 (10% 0/10 (0%) 0/10 (0%) 1/10 (10%) 1/10 (10%) |
|TERMINAL (d) 10/34 (29% 9/33 (27% 9/42 (21% 30/102 (29 19/74 (26% 4/31 (13%) 3/32 (9%) 3/30 (10%) 1/21 (5%) |
|FIRST INCIDENCE (DAYS) | 295 (I) 689 459 (I) 295 (I) 458 (I)| 736 (T) 736 (T) 458 (I) 458 (I) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.388N P=0.431N P=0.311N P=0.399 P=0.286N P=0.170 P=0.482N P=0.628 P=0.323 |
|INCIDENTAL TUMOR |P=0.472N P=0.418N P=0.363N P=0.424 P=0.325N P=0.208 P=0.482N P=0.628 P=0.424 |
|LOGISTIC REGRESSION |P=0.505N P=0.348N P=0.395N P=0.401 P=0.392N P=0.270 P=0.482N P=0.624N P=0.435 |
|COCHRAN-ARMITAGE |P=0.264N | P=0.354 |
|FISHER EXACT | P=0.452 P=0.349 P=0.108 P=0.496N P=0.481N P=0.622N P=0.511 |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 0/89 (0%) 3/60 (5%) 4/60 (7%) 8/189 (4% 12/160 (8% 3/58 (5%) 1/60 (2%) 2/60 (3%) 1/59 (2%) |
|ADJUSTED (b) 0.0% 7.7% 9.5% 7.0% 14.7% | 8.3% 3.1% 5.6% 4.8% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 1/10 (10% 0/10 (0%) 1/20 (5%) 1/20 (5%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/34 (0%) 2/33 (6%) 4/42 (10% 5/102 (5% 8/74 (11% 1/31 (3%) 1/32 (3%) 1/30 (3%) 1/21 (5%) |
|FIRST INCIDENCE (DAYS) | --- 459 (I) 729 (T) 459 (I) 395 | 620 736 (T) 604 736 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.017 * P=0.119 P=0.093 P=0.098 P=0.017 * P=0.503N P=0.305N P=0.504N P=0.436N |
|INCIDENTAL TUMOR |P=0.013 * P=0.119 P=0.093 P=0.113 P=0.013 * P=0.428N P=0.266N P=0.424N P=0.326N |
|LOGISTIC REGRESSION |P=0.014 * P=0.090 P=0.093 P=0.087 P=0.012 * P=0.427N P=0.290N P=0.484N P=0.357N |
|COCHRAN-ARMITAGE |P=0.034 * | P=0.369N |
|FISHER EXACT | P=0.063 P=0.025 * P=0.043 * P=0.004 ** P=0.297N P=0.484N P=0.303N |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 13/89 (15% 12/60 (20% 15/60 (25% 49/189 (26 31/160 (19 7/58 (12%) 4/60 (7%) 6/60 (10%) 6/59 (10%) |
|ADJUSTED (b) 33.4% 33.3% 33.5% 41.0% 37.4% | 20.5% 12.5% 16.8% 20.3% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 1/10 (10% 0/0 0/0 1/10 (10% 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 1/10 (10% 1/10 (10% 1/10 (10% 2/20 (10% 3/20 (15% 0/10 (0%) 0/10 (0%) 1/10 (10%) 1/10 (10%) |
|TERMINAL (d) 10/34 (29% 10/33 (30% 13/42 (31% 35/102 (34 24/74 (32% 5/31 (16%) 4/32 (13%) 4/30 (13%) 2/21 (10%) |
|FIRST INCIDENCE (DAYS) | 295 (I) 459 (I) 459 (I) 295 (I) 395 | 620 736 (T) 458 (I) 458 (I) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.338 P=0.565 P=0.547 P=0.174 P=0.421 P=0.278 P=0.249N P=0.516N P=0.498 |
|INCIDENTAL TUMOR |P=0.251 P=0.578 P=0.492 P=0.198 P=0.366 P=0.358 P=0.226N P=0.465N P=0.579N |
|LOGISTIC REGRESSION |P=0.234 P=0.551N P=0.453 P=0.165 P=0.299 P=0.421 P=0.238N P=0.472N P=0.589N |
|COCHRAN-ARMITAGE |P=0.518 | P=0.532 |
|FISHER EXACT | P=0.259 P=0.085 P=0.023 * P=0.221 P=0.245N P=0.474N P=0.487N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|Ovary |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 1/59 (2%) 0/60 (0%) 2/60 (3%) 0/60 (0%) |
|ADJUSTED (b) | | 3.2% 0.0% 6.7% 0.0% |
|INTERIM SACRIFICE 1 (c)| | |
|INTERIM SACRIFICE 2 (c)| | |
|INTERIM SACRIFICE 3 (c)| | |
|INTERIM SACRIFICE 4 (c)| | 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) | | 1/31 (3%) 0/32 (0%) 2/30 (7%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | | 736 (T) --- 736 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.553N P=0.494N P=0.488 P=0.578N |
|INCIDENTAL TUMOR | | P=0.553N P=0.494N P=0.488 P=0.578N |
|LOGISTIC REGRESSION | | P=0.553N P=0.494N P=0.488 P=0.578N |
|COCHRAN-ARMITAGE | | P=0.440N |
|FISHER EXACT | | P=0.496N P=0.506 P=0.496N |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 0/89 (0%) 0/26 (0%) 0/18 (0%) 0/89 (0%) 0/60 (0%) 8/59 (14%) 3/59 (5%) 5/58 (9%) 3/60 (5%) |
|ADJUSTED (b) 0.0% 0.0% 0.0% 0.0% 0.0% | 22.0% 8.8% 15.6% 14.3% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 0/0 0/0 0/34 (0%) 0/0 | 4/31 (13%) 2/31 (6%) 4/30 (13%) 3/21 (14%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- --- | 589 646 654 736 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) (e) | P=0.399N P=0.107N P=0.293N P=0.242N |
|INCIDENTAL TUMOR | (e) (e) (e) (e) (e) | P=0.316N P=0.081N P=0.275N P=0.162N |
|LOGISTIC REGRESSION | (e) (e) (e) (e) (e) | P=0.297N P=0.099N P=0.284N P=0.165N |
|COCHRAN-ARMITAGE | (e) | P=0.193N |
|FISHER EXACT | (e) (e) (e) (e) | P=0.102N P=0.290N P=0.097N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 1/89 (1%) 0/26 (0%) 0/18 (0%) 0/89 (0%) 0/60 (0%) 8/59 (14%) 4/59 (7%) 6/58 (10%) 3/60 (5%) |
|ADJUSTED (b) 2.9% 0.0% 0.0% 0.0% 0.0% | 22.0% 10.8% 17.5% 14.3% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 1/35 (3%) 0/0 0/0 0/34 (0%) 0/0 | 4/31 (13%) 2/31 (6%) 4/30 (13%) 3/21 (14%) |
|FIRST INCIDENCE (DAYS) | 729 (T) --- --- --- --- | 589 576 592 736 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.697N (e) (e) P=0.506N (e) | P=0.337N P=0.186N P=0.401N P=0.242N |
|INCIDENTAL TUMOR |P=0.697N (e) (e) P=0.506N (e) | P=0.236N P=0.147N P=0.373N P=0.162N |
|LOGISTIC REGRESSION |P=0.697N (e) (e) P=0.506N (e) | P=0.225N P=0.176N P=0.398N P=0.165N |
|COCHRAN-ARMITAGE |P=0.450N | P=0.151N |
|FISHER EXACT | P=0.774N P=0.832N P=0.500N P=0.597N P=0.181N P=0.402N P=0.097N |
|=================================================================================================================================|
| |
|Spleen |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 0/90 (0%) 0/28 (0%) 0/23 (0%) 0/90 (0%) 0/60 (0%) 0/59 (0%) 2/60 (3%) 0/60 (0%) 0/60 (0%) |
|ADJUSTED (b) 0.0% 0.0% 0.0% 0.0% 0.0% | 0.0% 4.4% 0.0% 0.0% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 0/1 (0%) 0/5 (0%) 0/34 (0%) 0/0 | 0/31 (0%) 0/32 (0%) 0/30 (0%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- --- | --- 503 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) (e) | P=0.421N P=0.249 (e) (e) |
|INCIDENTAL TUMOR | (e) (e) (e) (e) (e) | P=0.169N P=0.139 (e) (e) |
|LOGISTIC REGRESSION | (e) (e) (e) (e) (e) | P=0.343N P=0.227 (e) (e) |
|COCHRAN-ARMITAGE | (e) | P=0.377N |
|FISHER EXACT | (e) (e) (e) (e) | P=0.252 (e) (e) |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 0/90 (0%) 1/60 (2%) 1/60 (2%) 1/190 (1% 0/160 (0% 0/60 (0%) 0/60 (0%) 1/60 (2%) 2/60 (3%) |
|ADJUSTED (b) 0.0% 1.7% 2.4% 1.0% 0.0% | 0.0% 0.0% 3.3% 9.5% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 0/33 (0%) 1/42 (2%) 1/102 (1% 0/74 (0%) 0/31 (0%) 0/32 (0%) 1/30 (3%) 2/21 (10%) |
|FIRST INCIDENCE (DAYS) | --- 443 729 (T) 729 (T) --- | --- --- 736 (T) 736 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.258N P=0.500 P=0.536 P=0.712 (e) | P=0.041 * (e) P=0.493 P=0.157 |
|INCIDENTAL TUMOR |P=0.236N P=0.773 P=0.536 P=0.712 (e) | P=0.041 * (e) P=0.493 P=0.157 |
|LOGISTIC REGRESSION |P=0.248N P=0.304 P=0.536 P=0.712 (e) | P=0.041 * (e) P=0.493 P=0.157 |
|COCHRAN-ARMITAGE |P=0.237N | P=0.096 |
|FISHER EXACT | P=0.400 P=0.400 P=0.679 (e) | (e) P=0.500 P=0.248 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) 1/88 (1%) 0/29 (0%) 3/22 (14% 6/182 (3% 1/149 (1% 1/59 (2%) 1/60 (2%) 6/60 (10%) 0/60 (0%) |
|ADJUSTED (b) 2.9% 0.0% 51.1% 5.7% 1.4% | 2.6% 3.1% 18.2% 0.0% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 1/34 (3%) 0/2 (0%) 2/4 (50%) 4/100 (4% 1/74 (1%) 0/31 (0%) 1/32 (3%) 4/30 (13%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | 729 (T) --- 618 654 729 (T)| 657 736 (T) 660 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.106N P=0.974N P=0.010 ** P=0.405 P=0.579N P=0.409N P=0.754N P=0.061 P=0.554N |
|INCIDENTAL TUMOR |P=0.131N P=0.974N P=0.010 ** P=0.379 P=0.579N P=0.352N P=0.742N P=0.072 P=0.473N |
|LOGISTIC REGRESSION |P=0.105N P=0.974N P=0.008 ** P=0.397 P=0.579N P=0.349N P=0.756N P=0.061 P=0.509N |
|COCHRAN-ARMITAGE |P=0.162N | P=0.269N |
|FISHER EXACT | P=0.752N P=0.025 * P=0.274 P=0.606N P=0.748N P=0.060 P=0.496N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|Uterus |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # # |
|----------- | | |
|OVERALL (a) | | 1/60 (2%) 0/60 (0%) 2/60 (3%) 0/60 (0%) |
|ADJUSTED (b) | | 3.2% 0.0% 5.8% 0.0% |
|INTERIM SACRIFICE 1 (c)| | |
|INTERIM SACRIFICE 2 (c)| | |
|INTERIM SACRIFICE 3 (c)| | |
|INTERIM SACRIFICE 4 (c)| | 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) | | 1/31 (3%) 0/32 (0%) 0/30 (0%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | | 736 (T) --- 674 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.530N P=0.494N P=0.503 P=0.578N |
|INCIDENTAL TUMOR | | P=0.467N P=0.494N P=0.555 P=0.578N |
|LOGISTIC REGRESSION | | P=0.500N P=0.494N P=0.507 P=0.578N |
|COCHRAN-ARMITAGE | | P=0.442N |
|FISHER EXACT | | P=0.500N P=0.500 P=0.500N |
|=================================================================================================================================|
| |
|All Organs |
| Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 0/90 (0%) 0/60 (0%) 0/60 (0%) 0/190 (0% 0/160 (0% 1/60 (2%) 2/60 (3%) 1/60 (2%) 0/60 (0%) |
|ADJUSTED (b) 0.0% 0.0% 0.0% 0.0% 0.0% | 2.3% 5.7% 3.3% 0.0% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 0/33 (0%) 0/42 (0%) 0/102 (0% 0/74 (0%) 0/31 (0%) 1/32 (3%) 1/30 (3%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- --- | 598 668 736 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) (e) | P=0.298N P=0.504 P=0.757 P=0.530N |
|INCIDENTAL TUMOR | (e) (e) (e) (e) (e) | P=0.254N P=0.534 P=0.737N P=0.429N |
|LOGISTIC REGRESSION | (e) (e) (e) (e) (e) | P=0.257N P=0.506 P=0.760N P=0.493N |
|COCHRAN-ARMITAGE | (e) | P=0.235N |
|FISHER EXACT | (e) (e) (e) (e) | P=0.500 P=0.752N P=0.500N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 0/90 (0%) 1/60 (2%) 1/60 (2%) 2/190 (1% 0/160 (0% 0/60 (0%) 2/60 (3%) 0/60 (0%) 1/60 (2%) |
|ADJUSTED (b) 0.0% 2.6% 2.4% 1.7% 0.0% | 0.0% 4.4% 0.0% 3.8% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 0/33 (0%) 1/42 (2%) 1/102 (1% 0/74 (0%) 0/31 (0%) 0/32 (0%) 0/30 (0%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | --- 687 729 (T) 481 --- | --- 503 --- 695 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.281N P=0.505 P=0.536 P=0.497 (e) | P=0.588 P=0.249 (e) P=0.459 |
|INCIDENTAL TUMOR |P=0.286N P=0.527 P=0.536 P=0.638 (e) | P=0.546N P=0.139 (e) P=0.527 |
|LOGISTIC REGRESSION |P=0.275N P=0.486 P=0.536 P=0.429 (e) | P=0.654 P=0.211 (e) P=0.470 |
|COCHRAN-ARMITAGE |P=0.253N | P=0.641 |
|FISHER EXACT | P=0.400 P=0.400 P=0.460 (e) | P=0.248 (e) P=0.500 |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 0/90 (0%) 1/60 (2%) 1/60 (2%) 2/190 (1% 0/160 (0% 1/60 (2%) 4/60 (7%) 1/60 (2%) 1/60 (2%) |
|ADJUSTED (b) 0.0% 2.6% 2.4% 1.7% 0.0% | 2.3% 9.9% 3.3% 3.8% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 0/33 (0%) 1/42 (2%) 1/102 (1% 0/74 (0%) 0/31 (0%) 1/32 (3%) 1/30 (3%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | --- 687 729 (T) 481 --- | 598 503 736 (T) 695 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.281N P=0.505 P=0.536 P=0.497 (e) | P=0.434N P=0.193 P=0.757 P=0.720 |
|INCIDENTAL TUMOR |P=0.286N P=0.527 P=0.536 P=0.638 (e) | P=0.223N P=0.143 P=0.737N P=0.705N |
|LOGISTIC REGRESSION |P=0.275N P=0.486 P=0.536 P=0.429 (e) | P=0.346N P=0.204 P=0.760N P=0.755 |
|COCHRAN-ARMITAGE |P=0.253N | P=0.333N |
|FISHER EXACT | P=0.400 P=0.400 P=0.460 (e) | P=0.182 P=0.752N P=0.752N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|All Organs |
| Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 0/90 (0%) 0/60 (0%) 0/60 (0%) 0/190 (0% 0/160 (0% 4/60 (7%) 1/60 (2%) 0/60 (0%) 0/60 (0%) |
|ADJUSTED (b) 0.0% 0.0% 0.0% 0.0% 0.0% | 9.2% 2.9% 0.0% 0.0% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 0/33 (0%) 0/42 (0%) 0/102 (0% 0/74 (0%) 0/31 (0%) 0/32 (0%) 0/30 (0%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- --- | 396 688 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) (e) | P=0.105N P=0.184N P=0.065N P=0.083N |
|INCIDENTAL TUMOR | (e) (e) (e) (e) (e) | P=0.015N* P=0.262N P=0.091N P=0.009N** |
|LOGISTIC REGRESSION | (e) (e) (e) (e) (e) | P=0.077N P=0.200N P=0.066N P=0.053N |
|COCHRAN-ARMITAGE | (e) | P=0.088N |
|FISHER EXACT | (e) (e) (e) (e) | P=0.182N P=0.059N P=0.059N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 2/90 (2%) 5/60 (8%) 5/60 (8%) 10/190 (5% 2/160 (1% 15/60 (25%) 11/60 (18%) 5/60 (8%) 9/60 (15%) |
|ADJUSTED (b) 4.9% 13.2% 10.1% 8.3% 2.5% | 36.3% 28.2% 13.7% 28.9% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 1/10 (10% 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 2/33 (6%) 1/42 (2%) 3/102 (3% 1/74 (1%) 7/31 (23%) 5/32 (16%) 2/30 (7%) 3/21 (14%) |
|FIRST INCIDENCE (DAYS) | 627 617 459 (I) 435 612 | 396 577 625 400 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.051N P=0.207 P=0.274 P=0.351 P=0.436N P=0.493N P=0.253N P=0.019N* P=0.337N |
|INCIDENTAL TUMOR |P=0.096N P=0.203 P=0.081 P=0.398 P=0.663N P=0.064N P=0.279N P=0.015N* P=0.039N* |
|LOGISTIC REGRESSION |P=0.077N P=0.190 P=0.163 P=0.358 P=0.448N P=0.266N P=0.236N P=0.013N* P=0.148N |
|COCHRAN-ARMITAGE |P=0.030N* | P=0.215N |
|FISHER EXACT | P=0.091 P=0.091 P=0.199 P=0.455N P=0.253N P=0.013N* P=0.127N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 2/90 (2%) 5/60 (8%) 5/60 (8%) 10/190 (5% 2/160 (1% 13/60 (22%) 10/60 (17%) 5/60 (8%) 9/60 (15%) |
|ADJUSTED (b) 4.9% 13.2% 10.1% 8.3% 2.5% | 33.8% 26.0% 13.7% 28.9% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 0/10 (0%) 0/10 (0%) 1/10 (10% 0/20 (0%) 0/20 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 0/35 (0%) 2/33 (6%) 1/42 (2%) 3/102 (3% 1/74 (1%) 7/31 (23%) 5/32 (16%) 2/30 (7%) 3/21 (14%) |
|FIRST INCIDENCE (DAYS) | 627 617 459 (I) 435 612 | 520 577 625 400 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.051N P=0.207 P=0.274 P=0.351 P=0.436N P=0.483 P=0.313N P=0.045N* P=0.503N |
|INCIDENTAL TUMOR |P=0.096N P=0.203 P=0.081 P=0.398 P=0.663N P=0.220N P=0.285N P=0.028N* P=0.157N |
|LOGISTIC REGRESSION |P=0.077N P=0.190 P=0.163 P=0.358 P=0.448N P=0.437N P=0.281N P=0.026N* P=0.301N |
|COCHRAN-ARMITAGE |P=0.030N* | P=0.344N |
|FISHER EXACT | P=0.091 P=0.091 P=0.199 P=0.455N P=0.322N P=0.036N* P=0.240N |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 36/90 (40% 25/60 (42% 34/60 (57% 60/190 (32 27/160 (17 24/60 (40%) 22/60 (37%) 25/60 (42%) 15/60 (25%) |
|ADJUSTED (b) 75.3% 64.5% 68.9% 49.9% 33.7% | 59.1% 62.4% 67.0% 49.0% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 2/10 (20% 0/0 0/0 1/10 (10% 1/20 (5%) |
|INTERIM SACRIFICE 4 (c 5/10 (50% 2/10 (20% 3/10 (30% 2/20 (10% 2/20 (10% 1/10 (10%) 0/10 (0%) 1/10 (10%) 2/10 (20%) |
|TERMINAL (d) 24/35 (69% 20/33 (61% 27/42 (64% 44/102 (43 23/74 (31% 15/31 (48%) 19/32 (59%) 18/30 (60%) 7/21 (33%) |
|FIRST INCIDENCE (DAYS) | 295 (I) 443 459 (I) 295 (I) 295 (I)| 458 (I) 633 458 (I) 458 (I) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P<0.001N** P=0.107N P=0.237N P=0.003N** P<0.001N** P=0.404N P=0.382N P=0.470 P=0.351N |
|INCIDENTAL TUMOR |P<0.001N** P=0.080N P=0.361N P=0.002N** P<0.001N** P=0.214N P=0.321N P=0.565N P=0.136N |
|LOGISTIC REGRESSION |P<0.001N** P=0.083N P=0.509N P=0.001N** P<0.001N** P=0.143N P=0.370N P=0.546 P=0.124N |
|COCHRAN-ARMITAGE |P<0.001N** | P=0.040N* |
|FISHER EXACT | P=0.486 P=0.033 * P=0.106N P<0.001N** P=0.426N P=0.500 P=0.059N |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 0.01 PPM 0.05 PPM 0.2 PPM 0.5 PP| CONTROL 0.01 PPM 0.05 PPM 0.2 PP |
| | SE65 SE42 | M |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 13/90 (14% 15/60 (25% 20/60 (33% 30/190 (16 14/160 (9% 21/60 (35%) 22/60 (37%) 11/60 (18%) 12/60 (20%) |
|ADJUSTED (b) 29.1% 33.9% 40.4% 23.7% 17.0% | 47.6% 48.7% 27.2% 39.3% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/20 (0%) |
|INTERIM SACRIFICE 4 (c 2/10 (20% 1/10 (10% 1/10 (10% 1/20 (5%) 1/20 (5%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 0/10 (0%) |
|TERMINAL (d) 5/35 (14% 6/33 (18% 13/42 (31% 12/102 (12 9/74 (12% 9/31 (29%) 9/32 (28%) 4/30 (13%) 5/21 (24%) |
|FIRST INCIDENCE (DAYS) | 459 (I) 443 459 (I) 393 395 | 396 503 411 400 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P=0.003N** P=0.385 P=0.244 P=0.327N P=0.060N P=0.219N P=0.533 P=0.048N* P=0.256N |
|INCIDENTAL TUMOR |P=0.006N** P=0.448 P=0.046 * P=0.225N P=0.133N P=0.002N** P=0.471 P=0.023N* P=0.013N* |
|LOGISTIC REGRESSION |P=0.005N** P=0.380 P=0.078 P=0.280N P=0.079N P=0.028N* P=0.570N P=0.021N* P=0.072N |
|COCHRAN-ARMITAGE |P<0.001N** | P=0.030N* |
|FISHER EXACT | P=0.080 P=0.006 ** P=0.460 P=0.120N P=0.500 P=0.031N* P=0.051N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # # | # # # # |
|----------- | | |
|OVERALL (a) 44/90 (49% 35/60 (58% 43/60 (72% 81/190 (43 37/160 (23 35/60 (58%) 37/60 (62%) 34/60 (57%) 22/60 (37%) |
|ADJUSTED (b) 82.5% 77.0% 79.5% 61.0% 43.5% | 73.9% 80.3% 78.5% 62.2% |
|INTERIM SACRIFICE 1 (c 0/10 (0%) 0/0 0/0 0/0 0/10 (0%) |
|INTERIM SACRIFICE 2 (c 0/10 (0%) 0/0 0/0 0/10 (0%) 0/10 (0%) |
|INTERIM SACRIFICE 3 (c 2/10 (20% 0/0 0/0 1/10 (10% 1/20 (5%) |
|INTERIM SACRIFICE 4 (c 7/10 (70% 3/10 (30% 4/10 (40% 3/20 (15% 3/20 (15% 1/10 (10%) 0/10 (0%) 1/10 (10%) 2/10 (20%) |
|TERMINAL (d) 26/35 (74% 23/33 (70% 31/42 (74% 52/102 (51 28/74 (38% 19/31 (61%) 23/32 (72%) 21/30 (70%) 9/21 (43%) |
|FIRST INCIDENCE (DAYS) | 295 (I) 443 459 (I) 295 (I) 295 (I)| 396 340 411 400 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE |P<0.001N** P=0.238N P=0.252N P=0.005N** P<0.001N** P=0.216N P=0.494 P=0.522N P=0.264N |
|INCIDENTAL TUMOR |P<0.001N** P=0.149N P=0.566 P<0.001N** P<0.001N** P=0.001N** P=0.407 P=0.482N P=0.007N** |
|LOGISTIC REGRESSION |P<0.001N** P=0.100N P=0.498N P<0.001N** P<0.001N** P=0.009N** P=0.495 P=0.447N P=0.027N* |
|COCHRAN-ARMITAGE |P<0.001N** | P=0.002N** |
|FISHER EXACT | P=0.167 P=0.004 ** P=0.196N P<0.001N** P=0.426 P=0.500N P=0.014N* |
|=================================================================================================================================|
DATE: 09/15/94 EXPERIMENT: 05114 TEST: 02 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- HEXACHLOROCYCLOPENTADIENE (HCCPD)
MALE TERMINAL SACRIFICE AT 105 WEEKS
FEMALE TERMINAL SACRIFICE AT 106 WEEKS
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(c) Observed incidence at interim kill.
Male interim sacrifices(days): 183 232 295 458
Female interim sacrifices(days): 458
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).